Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: a Circulation mechanistic paper identifies FMO2 as a mitochondria–ER contact (MAM) regulator that prevents pathological hypertrophy; a long-term post-hoc analysis shows tafamidis markedly improves survival in earlier-stage transthyretin amyloid cardiomyopathy; and a pragmatic randomized trial demonstrates AI-ECG decision support increases early detection of low ejection fraction in inpatients without increasing testing burden.
Summary
Three impactful cardiology studies stood out today: a Circulation mechanistic paper identifies FMO2 as a mitochondria–ER contact (MAM) regulator that prevents pathological hypertrophy; a long-term post-hoc analysis shows tafamidis markedly improves survival in earlier-stage transthyretin amyloid cardiomyopathy; and a pragmatic randomized trial demonstrates AI-ECG decision support increases early detection of low ejection fraction in inpatients without increasing testing burden.
Research Themes
- ER-mitochondria crosstalk and cardiac remodeling mechanisms
- Disease-modifying therapy timing in transthyretin amyloid cardiomyopathy
- AI-enabled diagnostic decision support for heart failure detection
Selected Articles
1. FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondria Association Through Interaction With IP3R2-Grp75-VDAC1.
This mechanistic study identifies FMO2 as a previously unrecognized MAM-resident regulator that binds the IP3R2–Grp75–VDAC1 complex, preserving ER–mitochondria contacts and mitochondrial Ca2+ handling to prevent pathological hypertrophy. FMO2 expression is decreased in hypertrophy; genetic loss worsens, while cardiac overexpression prevents, disease progression in vivo.
Impact: Revealing a MAM-anchored mechanism that directly links ER–mitochondria coupling to pathological hypertrophy opens a therapeutic avenue targeting subcellular contacts. It advances understanding of cardiomyocyte calcium microdomain regulation in disease.
Clinical Implications: FMO2 and MAM integrity may serve as therapeutic targets and biomarkers for hypertrophic remodeling and heart failure. Strategies that stabilize IP3R2–Grp75–VDAC1 interactions or enhance FMO2 function warrant translational testing.
Key Findings
- FMO2 was identified as an ER-resident component enriched at mitochondria-associated ER membranes (MAMs).
- FMO2 expression decreased during pathological cardiac hypertrophy in human and mouse hearts.
- Cardiac FMO2 deletion worsened, while overexpression prevented, hypertrophy and heart failure progression in vivo.
- FMO2 binds the IP3R2–Grp75–VDAC1 complex, maintaining ER–mitochondria contacts and mitochondrial Ca2+ regulation.
- Multi-omics (bulk RNA-seq) and MAM-targeted mass spectrometry supported FMO2’s role in MAM structure and function.
Methodological Strengths
- Integrated human tissue transcriptomics with MAM-targeted proteomics and in vivo genetic mouse models
- Convergent validation across neonatal rat cardiomyocytes, AAV9 overexpression, and knockout systems
Limitations
- Preclinical study without direct human interventional data
- Translational pharmacology (drug-like FMO2 modulators) was not evaluated
Future Directions: Develop small-molecule or gene therapy approaches to enhance FMO2 or stabilize IP3R2–Grp75–VDAC1, test in large-animal hypertrophy/heart failure models, and explore biomarker potential of MAM integrity in patients.
BACKGROUND: Cardiac hypertrophy, as an important pathological change, contributes to heart failure. Recent studies indicate that the mitochondria-associated endoplasmic reticulum membranes (MAMs) play key roles in this pathological process. However, the molecular mechanism remains unclear. This study aims to elucidate the effects and mechanisms of MAM-resident FMO2 (flavin-containing monooxygenase 2) in cardiac hypertrophy and heart failure. METHODS: We performed bulk RNA-sequencing analysis using heart tissue from patients with cardiac hypertrophy and carried out MAM-targeted mass spectrometry analysis using heart tissue from a mouse model of pathological cardiac hypertrophy. In vitro cell culture using neonatal rat cardiomyocytes was used to study how MAMs formation affected cardiomyocyte functions. By generating different genetic mouse models combined with using adeno-associated virus 9 under the cardiac troponin T promoter techniques, we further investigated and confirmed the effects of MAM structure changes on cardiac hypertrophy. RESULTS: We detected an unexpected component of MAMs structure, which was the FMO2, an endoplasmic reticulum-resident protein. FMO2 levels decreased during pathological cardiac hypertrophy. The deletion and overexpression of FMO2 can either worsen or prevent the pathological heart failure progression in vivo, respectively. Our data further demonstrated that FMO2 localizes to MAM structure, where it binds to inositol 1,4,5-trisphosphate type 2 receptor (IP3R2) as a component of the IP3R2-Grp75 (glucose-regulated protein 75)-VDAC1 (voltage-dependent anion channel protein 1) complex, maintaining endoplasmic reticulum-mitochondria contact and regulating mitochondrial Ca
2. Artificial intelligence-assisted diagnosis and prognostication in low ejection fraction using electrocardiograms in inpatient department: a pragmatic randomized controlled trial.
In a pragmatic RCT of 13,631 inpatients, AI-ECG decision support increased new low LVEF (≤50%) diagnoses (HR 1.50 overall; 13.0% vs 8.9% in high-risk) without increasing echocardiography volume, while improving positive predictive value and cardiology consultation rates among high-risk patients.
Impact: Demonstrates scalable AI-ECG deployment can boost actionable detection of systolic dysfunction under non-cardiologist care without adding resource burden. It provides high-quality evidence for integrating AI decision support into inpatient workflows.
Clinical Implications: Hospitals can implement AI-ECG triage to prioritize echocardiography and specialist evaluation for high-risk inpatients, accelerating heart failure diagnosis and initiation of guideline-directed therapy.
Key Findings
- AI-ECG increased new low LVEF diagnoses within 30 days (overall HR 1.50; high-risk 13.0% vs 8.9%).
- Echocardiography utilization remained similar (17.1% vs 17.3%), but positive predictive value for low EF improved (34.2% vs 20.2%).
- Among high-risk patients, cardiology consultation rates increased (29.3% vs 23.5%).
Methodological Strengths
- Large pragmatic randomized controlled design with 13,631 inpatients
- Pre-specified primary outcome and balanced resource utilization assessment
Limitations
- Single-center setting may limit generalizability
- Short follow-up and lack of hard clinical outcomes beyond diagnostic yield
Future Directions: Multicenter trials assessing downstream outcomes (time to therapy, HF hospitalizations, mortality) and cost-effectiveness of AI-ECG guided pathways.
BACKGROUND: Early diagnosis of low ejection fraction (EF) remains challenging despite being a treatable condition. This study aimed to evaluate the effectiveness of an electrocardiogram (ECG)-based artificial intelligence (AI)-assisted clinical decision support tool in improving the early diagnosis of low EF among inpatient patients under non-cardiologist care. METHODS: We conducted a pragmatic randomized controlled trial at an academic medical center in Taiwan. 13,631 inpatient patients were randomized to either the intervention group (n = 6,840) receiving AI-generated ECG results or the control group (n = 6,791) following standard care. The primary outcome was the incidence of newly diagnosed low EF (≤ 50%) within 30 days following the ECG. Secondary outcomes included echocardiogram utilization rates, positive predictive value for low EF detection, and cardiology consultation rates. Statistical analysis included hazard ratios (HR) with 95% confidence intervals (CI) for time-to-event outcomes and chi-square tests for categorical variables. RESULTS: The intervention significantly increased the detection of newly diagnosed low EF in the overall cohort (1.5% vs. 1.1%, HR 1.50, 95% CI: 1.11-2.03, P = 0.023), with a more pronounced effect among AI-identified high-risk patients (13.0% vs. 8.9%, HR 1.55, 95% CI: 1.08-2.21). While overall echocardiogram utilization remained similar between groups (17.1% vs. 17.3%, HR 1.00, 95% CI: 0.92-1.09), the intervention group demonstrated higher positive predictive value for identifying low EF among patients receiving echocardiogram (34.2% vs. 20.2%, p < 0.001). Post-hoc analysis revealed increased cardiology consultation rates among high-risk patients in the intervention group (29.3% vs. 23.5%, p = 0.027). CONCLUSIONS: Implementation of an AI-ECG algorithm enhanced the early diagnosis of low EF in the inpatient setting, primarily by improving diagnostic efficiency rather than increasing overall healthcare utilization. The tool was particularly effective in identifying high-risk patients who benefited from increased specialist consultation and more targeted diagnostic testing. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05117970.
3. Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage.
Across ATTR-ACT and its LTE with up to 90 months’ follow-up, continuous tafamidis reduced all-cause and CV mortality and hospitalizations in NAC stage I/II ATTR-CM (HR 0.43 and 0.51 for all-cause mortality), with favorable trends in stage III. Benefits appeared earlier in stage I, underscoring the value of early diagnosis and treatment.
Impact: This analysis extends randomized evidence by stage and long-term follow-up, demonstrating that earlier tafamidis initiation yields greater survival and quality-of-life benefits, guiding stage-specific treatment decisions.
Clinical Implications: Screen early for ATTR-CM and initiate tafamidis at NAC stage I/II to optimize survival and reduce hospitalizations; delays to therapy may attenuate benefits, particularly in advanced disease.
Key Findings
- Continuous tafamidis lowered all-cause mortality versus placebo-to-tafamidis in NAC stage I (36% vs 61%; HR 0.43) and II (55% vs 74%; HR 0.51).
- CV mortality and hospitalization reductions paralleled all-cause mortality benefits in stages I/II.
- Survival curves diverged early at stage I, later at higher stages; KCCQ declines were smaller with tafamidis, especially in earlier stages.
Methodological Strengths
- Long-term (up to 90 months) follow-up across RCT and extension populations
- Stage-stratified analyses linking treatment timing to outcomes
Limitations
- Post-hoc nature may introduce residual confounding and selection bias
- Stage III subgroup underpowered for definitive mortality effects
Future Directions: Prospective studies to validate stage-specific initiation thresholds and explore combination strategies (e.g., TTR silencers) across disease stages.
AIMS: Tafamidis is an approved treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) based on the 30-month Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). This post-hoc analysis evaluated outcomes in ATTR-ACT and its long-term extension study (LTE) by baseline National Amyloidosis Centre (NAC) stage. METHODS AND RESULTS: Patients received either the approved dose of tafamidis 80 mg or placebo in ATTR-ACT and tafamidis in the LTE. All-cause and cardiovascular (CV)-related mortality, CV-related hospitalizations, and Kansas City Cardiomyopathy Questionnaire overall summary and clinical summary (KCCQ-OS/CS) scores were assessed up to 90 months of follow-up. Of 353 patients, 350 were evaluable for NAC staging. At baseline, 42%, 38%, and 20% were NAC stage I, II, and III, respectively. At the end of study, all-cause mortality was lower in the continuous tafamidis versus placebo to tafamidis groups at NAC stages I (36% vs. 61%; hazard ratio [HR] 0.43, p < 0.001) and II (55% vs. 74%; HR 0.51, p = 0.003); with a numerical trend at stage III (69% vs. 88%; HR 0.75, p = 0.298). Survival curves diverged early in patients at NAC stage I, but later at higher stages. Similar patterns were observed for CV-related mortality. Continuous tafamidis versus placebo to tafamidis groups at NAC stages I/II had lower CV-related hospitalization rates and frequently smaller declines in KCCQ-OS/CS scores over follow-up; with favourable trends at stage III. CONCLUSIONS: Tafamidis treatment reduced the risk of mortality and hospitalization in patients with NAC stages I/II ATTR-CM, with favourable trends at stage III. This illustrates the importance of early diagnosis and initiation of disease-modifying therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01994889, NCT02791230.